Morgan Stanley
MLTX icon

Morgan Stanley’s MoonLake Immunotherapeutics MLTX Stock Holding History

Morgan Stanley’s Portfolio MLTX Stock Details MLTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$11M Sell
563,602
-50,880
-8% -$922K ﹤0.01% 3606
2026
Q1 		$11.5M Sell
614,482
-430,099
-41% -$7.12M ﹤0.01% 3461
2025
Q4 		$13.8M Buy
1,044,581
+787,926
+307% +$9.3M ﹤0.01% 3301
2025
Q3 		$1.84M Buy
256,655
+213,416
+494% +$11.1M ﹤0.01% 4838
2025
Q2 		$2.04M Sell
43,239
-11,092
-20% -$452K ﹤0.01% 4687
2025
Q1 		$2.12M Buy
54,331
+7,187
+15% +$310K ﹤0.01% 4569
2024
Q4 		$2.55M Sell
47,144
-83,454
-64% -$4.26M ﹤0.01% 4536
2024
Q3 		$6.58M Buy
130,598
+61,571
+89% +$2.89M ﹤0.01% 3744
2024
Q2 		$3.04M Sell
69,027
-160,155
-70% -$6.78M ﹤0.01% 4276
2024
Q1 		$11.5M Buy
229,182
+162,668
+245% +$8.82M ﹤0.01% 3230
2023
Q4 		$4.02M Buy
66,514
+57,063
+604% +$2.94M ﹤0.01% 4081
2023
Q3 		$539K Sell
9,451
-149,974
-94% -$8.28M ﹤0.01% 5136
2023
Q2 		$8.13M Buy
159,425
+126,906
+390% +$3.41M ﹤0.01% 3359
2023
Q1 		$696K Buy
32,519
+5,154
+19% +$86.7K ﹤0.01% 5065
2022
Q4 		$287K Buy
27,365
+24,265
+783% +$216K ﹤0.01% 5511
2022
Q3 		$24K Buy
+3,100
New +$21.9K ﹤0.01% 6715
2022
Q1 		– Sell
-13,449
Closed -$133K – 8057
2021
Q4 		$133K Hold
13,449
– – ﹤0.01% 6278
2021
Q3 		$132K Buy
13,449
+7,549
+128% +$75.3K ﹤0.01% 6215
2021
Q2 		$61K Sell
5,900
-1
-0% -$10 ﹤0.01% 6587
2021
Q1 		$60K Buy
5,901
+5,900
+590,000% +$65K ﹤0.01% 6273
2020
Q4 		$0 Buy
+1
New +$11 ﹤0.01% 7076

Other funds holding MLTX

BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
WAM
Weiss Asset Management Boston, Massachusetts $9.54B AUM 55.06% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Morgan Stanley's MLTX Position: Q2 2026 in Review

Morgan Stanley reduced its MoonLake Immunotherapeutics (MLTX) stake by 8.3% in Q2 2026, selling an estimated $922K and leaving 563,602 shares worth $11M. The position accounts for ﹤0.01% of the portfolio, ranked #3606.

Morgan Stanley first reported a position in MLTX in Q4 2020 and has held it in 21 quarters since. The position peaked at $13.8M in Q4 2025. 173 funds tracked by Wall St. Rank hold MLTX as of Q2 2026.

  • Morgan Stanley held 563,602 shares of MoonLake Immunotherapeutics worth $11M as of Q2 2026.
  • Morgan Stanley sold 50,880 MoonLake Immunotherapeutics shares in Q2 2026, an estimated $922K.
  • MoonLake Immunotherapeutics made up ﹤0.01% of Morgan Stanley's portfolio in Q2 2026, its #3606 holding.
  • Morgan Stanley first reported a position in MoonLake Immunotherapeutics in Q4 2020 and has held it in 21 quarters since.
  • Morgan Stanley's MoonLake Immunotherapeutics position peaked at $13.8M in Q4 2025.
  • 173 funds tracked by Wall St. Rank held MoonLake Immunotherapeutics as of Q2 2026.

Based on Morgan Stanley's 13F filing for Q2 2026, filed 13 Aug 2026.